Advertisement
Canada markets open in 4 hours 40 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7331
    +0.0008 (+0.10%)
     
  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     
  • Bitcoin CAD

    87,793.12
    +803.39 (+0.92%)
     
  • CMC Crypto 200

    1,389.49
    -7.05 (-0.50%)
     
  • GOLD FUTURES

    2,359.50
    +17.00 (+0.73%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,742.00
    +174.50 (+0.99%)
     
  • VOLATILITY

    15.52
    +0.15 (+0.98%)
     
  • FTSE

    8,110.19
    +31.33 (+0.39%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6819
    -0.0002 (-0.03%)
     

Today's Research Reports on Trending Tickers: Canopy Growth and Constellation Brands

NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Both Constellation Brands and Canopy Growth were gaining positive remarks this week sending shares higher.

The Market Edge Initiates Coverage on:

Canopy Growth Corporation
https://marketedgereport.com/report/CGC/

Constellation Brands, Inc.
https://marketedgereport.com/report/STZ/

Canopy Growth Corporation shares were up almost 7% yesterday on almost 8 million shares traded. The Canadian marijuana company didn't have any immediate news but CNBC's Jim Cramer said the company remains the best way to invest in the growing Canadian cannabis space. "Even with Altria investing in Cronos, I believe that Canopy Growth remains the best way to play the Canadian cannabis market,” said the host of "Mad Money" on Tuesday. He added, "Can Cronos compare to Canopy Growth? Honestly, it isn’t really a fair comparison. Canopy’s significantly larger than Cronos — we’re talking about an $11.4 billion company versus a $2.3 billion company. Canopy’s got scale, and scale matters in this business." Cramer also said, "Canopy Growth is already leading Cronos in 12 out of 13 cannabis product categories… Cronos leads in one out of those 13. That’s because Canopy sells many more types of products: flowers, oil, pre-rolls, soft gels, and vapes. Cronos only sells flowers, oil and pre-rolls." Cramer noted that Canopy already has patents on 137 types of products.

ADVERTISEMENT

Access The Market Edge's Canopy Growth Corporation Research Report:
https://marketedgereport.com/report/CGC/

Constellation Brands, Inc. shares were up modestly in Tuesday's session on about 2 million shares traded. The Corona beer maker received some optimistic remarks from one of the top marijuana analysts. Vivien Azer of Cowen has remarked that since Constellation first announced its $4 billion investment in Canopy Growth, shares have fallen almost 15 percent. This is a good entry point according to the analyst. "Constellation Brands remains our overall top pick as we approach 2019. Best in class revenue growth within U.S. beer, coupled with strong profitability has afforded them the opportunity to leverage this strong operating performance,” Azer wrote. She added, "While Constellation’s sales have slowed some, they are still growing double digits in Nielsen tracked channels." She said there is still enough room for the company “to continue to capture market share gains and generate strong revenue growth.” Cowen has named Constellation Brands a top stock idea for 2019.

Access The Market Edge's Constellation Brands, Inc. Research Report:
https://marketedgereport.com/report/STZ/

Our Actionable Research on Canopy Growth Corporation (NYSE: CGC) and Constellation Brands, Inc. (NYSE: STZ) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: The Market Edge